Fiorelli G, De Bellis A, Longo A, Natali A, Costantini A, Serio M
Department of Clinical Physiopathology, University of Florence, Italy.
J Clin Endocrinol Metab. 1989 Apr;68(4):740-3. doi: 10.1210/jcem-68-4-740.
We characterized the epidermal growth factor (EGF) receptor in the membrane fraction of prostatic tissue from men with benign prostatic hyperplasia (BPH). The maximum specific binding of [125I]EGF to the BPH membrane fraction was achieved after 30-min incubation at 35 C. Analysis of the binding data revealed two classes of binding sites, one of high affinity [Kd, 2.5 +/- 0.5 (+/- SE) x 10(-11) mol/L] and one of lower affinity (2.2 +/- 0.3 x 10(-9) mol/L). [125I]EGF binding was inhibited by excess EGF, but not by insulin, proinsulin, fibroblast growth factor, or insulin-like growth factors I and II. In prostatic tissue of men with BPH treated for 3 months with the GnRH agonist analog Goserelin (Zoladex, depot formulation), the binding capacities of both sites were significantly higher than those of BPH tissue from untreated men (P less than 0.001). These results demonstrate that prostatic tissue from men with BPH contains two classes of specific binding sites for EGF, and their levels are modulated by chronic GnRH agonists treatment.
我们对良性前列腺增生（BPH）男性前列腺组织膜组分中的表皮生长因子（EGF）受体进行了特性分析。[125I]EGF与BPH膜组分的最大特异性结合在35℃孵育30分钟后达到。结合数据分析显示存在两类结合位点，一类具有高亲和力[解离常数（Kd），2.5±0.5（±标准误）×10-11摩尔/升]，另一类亲和力较低（2.2±0.3×10-9摩尔/升）。过量的EGF可抑制[125I]EGF结合，但胰岛素、胰岛素原、成纤维细胞生长因子或胰岛素样生长因子I和II则无此作用。在接受促性腺激素释放激素（GnRH）激动剂类似物戈舍瑞林（诺雷德，长效制剂）治疗3个月的BPH男性的前列腺组织中，两类位点的结合能力均显著高于未治疗男性的BPH组织（P<0.001）。这些结果表明，BPH男性的前列腺组织含有两类EGF特异性结合位点，且其水平受慢性GnRH激动剂治疗的调节。
